🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

529 results for “Teva” Clear

  1. Laquinimod

    Teva Pharma GmbH

    Lupus Nephritis

    phase 2 small molecule completed

    1 trial

  2. Laquinimod 0.6

    Teva Pharma GmbH

    Relapsing Multiple Sclerosis

    phase 2 small molecule terminated

    1 trial

  3. Larazotide Acetate

    Teva Pharma GmbH

    Celiac Disease

    phase 2 small molecule completed

    1 trial

  4. Liposomal doxorubicin hydrochloride

    Teva Pharma GmbH

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  5. Metronidazole

    Teva Pharma GmbH

    Bacterial Vaginosis

    phase 2 small molecule completed

    1 trial

  6. Modakafusp Alfa

    Teva Generics B.V

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  7. Modakafusp Alfa

    Teva Pharma GmbH

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  8. Modakafusp alfa

    Teva Pharma GmbH

    Multiple Myeloma

    phase 2 small molecule terminated

    3 trials

  9. Mometasone furoate

    Teva Pharma GmbH

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  10. NEXPOVIO 20 mg film-coated tablets, HOLOXAN 1 g polvere per soluzione per infusione, Decadron “8 mg/2 ml Soluzione iniettabile”, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione.

    Fondazione Telethon ETS

    Relapsed or Refractory Peripheral T-cell Lymphomas

    phase 2 small molecule active

    1 trial

  11. Nebulized IVX-0142

    Teva Pharma GmbH

    Asthma

    phase 2 small molecule completed

    1 trial

  12. ONCOVIN 1 mg, solution injectable, CARBOPLATINE TEVA 10 mg/ml, solution pour perfusion, ENDOXAN 1000 mg, poudre pour solution injectable, ETOPOSIDE TEVA 20 mg/ml, solution à diluer pour perfusion, TEPADINA 15 mg powder for concentrate for solution for infusion, THIOTEPA GENOPHARM 15 mg, lyophilisat pour usage parentéral

    The George Institute

    Retinoblastoma

    phase 2 small molecule active

    1 trial

  13. Obatoclax

    Teva Pharma GmbH

    Extensive-stage Small Cell Lung Cancer

    phase 2 small molecule completed

    1 trial

  14. Obatoclax

    Teva Pharma GmbH

    AML

    phase 2 small molecule completed

    1 trial

  15. Obatoclax Mesylate

    Teva Pharma GmbH

    Metastatic Melanoma

    phase 2 small molecule terminated

    1 trial

  16. Obatoclax mesylate

    Teva Pharma GmbH

    Mantle-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  17. Obatoclax mesylate

    Teva Pharma GmbH

    Lymphoma, Follicular

    phase 2 small molecule completed

    1 trial

  18. Obatoclax mesylate (GX15-070MS)

    Teva Pharma GmbH

    Myelodysplastic Syndromes

    phase 2 small molecule completed

    1 trial

  19. Obatoclax mesylate (GX15-070MS)

    Teva Pharma GmbH

    Hodgkin's Lymphoma

    phase 2 small molecule completed

    1 trial

  20. Obatoclax mesylate (GX15-070MS)

    Teva Pharma GmbH

    Myelofibrosis

    phase 2 small molecule completed

    1 trial

  21. Obatoclax mesylate 250 ml

    Teva Pharma GmbH

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  22. Olaparib, ETOPOSIDE TEVA 20 mg/ml, concentrato per soluzione per infusione, Cisplatino Sandoz 1 mg/ml – Concentrato per soluzione per infusione, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Olaparib, CARBOPLATINO TEVA 10 mg/ml

    Istituto Gentili S.r.l.

    Extensive-Stage Small-Cell Lung Cancer (ES SCLC)

    phase 2 small molecule active

    1 trial

  23. Omacetaxine

    Teva Pharma GmbH

    Leukemia

    phase 2 small molecule terminated

    2 trials

  24. Omacetaxine

    Teva Pharma GmbH

    Acute Myelogenous Leukemia (AML)

    phase 2 small molecule terminated

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources